Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (341-350 of 706) with videos related to

Pageof 71
Sort By:
Circulation|January 13, 2010
Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registryCaroline S Fox, Paul Muntner, Anita Y Chen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 1, 2018
Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fractionNasrien E Ibrahim, Hanna K Gaggin, Alexander Turchin, et al.
Clinical Cardiology|May 20, 2008
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
American Heart Journal|September 20, 2024
Enrollment strategies in the era of digital revolution: Experience from a remote health management programShahzad Hassan, Lee-Shing Chang, Daniel Gabovitch, et al.
Circulation|April 2, 2008
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarctionMarc S Sabatine, David A Morrow, Luke J Higgins, et al.
Journal of the American College of Cardiology|November 26, 2002
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudyMarc S Sabatine, David A Morrow, Christopher P Cannon, et al.
Circulation|August 13, 2003
Soluble CD40L: risk prediction after acute coronary syndromesNerea Varo, James A de Lemos, Peter Libby, et al.
American Heart Journal|June 7, 2011
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22)Sean R Wilson, Marc S Sabatine, Stephen D Wiviott, et al.
Diabetes, Obesity & Metabolism|March 10, 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CVSamuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, et al.
Pageof 71

Showing results (341-350 of 706) with videos related to

Sort By:
Pageof 71
Circulation|January 13, 2010
Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registryCaroline S Fox, Paul Muntner, Anita Y Chen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 1, 2018
Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fractionNasrien E Ibrahim, Hanna K Gaggin, Alexander Turchin, et al.
Clinical Cardiology|May 20, 2008
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
Clinical Cardiology|May 20, 2008
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary interventionEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.
American Heart Journal|September 20, 2024
Enrollment strategies in the era of digital revolution: Experience from a remote health management programShahzad Hassan, Lee-Shing Chang, Daniel Gabovitch, et al.
Circulation|April 2, 2008
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarctionMarc S Sabatine, David A Morrow, Luke J Higgins, et al.
Journal of the American College of Cardiology|November 26, 2002
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudyMarc S Sabatine, David A Morrow, Christopher P Cannon, et al.
Circulation|August 13, 2003
Soluble CD40L: risk prediction after acute coronary syndromesNerea Varo, James A de Lemos, Peter Libby, et al.
American Heart Journal|June 7, 2011
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22)Sean R Wilson, Marc S Sabatine, Stephen D Wiviott, et al.
Diabetes, Obesity & Metabolism|March 10, 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CVSamuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, et al.
Pageof 71